Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of E-Vim Vaccine CVX1 with or without Ici in the Treatment of Subjects with Muscle Invasive Bladder Cancer (Mibc) or Localized or Locally Advanced Renal Cell Cancer (RCC).

2025-523781-25-00 Protocol CC-CVx1-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 2 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol CC-CVx1-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 83
Countries 1
Sites 4

metastatic solid cancer, muscle invasive bladder cancer, localized or locally advanced renal cell cancer (RCC)

Key facts

Sponsor
CimCure B.V.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
2 Apr 2026 → ongoing
Decision date (initial)
2026-01-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

metastatic solid cancer, muscle invasive bladder cancer, localized or locally advanced renal cell cancer (RCC)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CimCure B.V.

Sponsor organisation
CimCure B.V.
Address
Plesmanlaan 125
City
Amsterdam
Postcode
1066 CX
Country
Netherlands

Scientific contact point

Organisation
CimCure B.V.
Contact name
Arjan Griffioen

Public contact point

Organisation
CimCure B.V.
Contact name
Diederik Engbersen

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 83 4
Rest of world 0

Investigational sites

Netherlands

4 sites · Ongoing, recruiting
Netherlands Cancer Institute
Medical Oncology, Plesmanlaan 121, 1066 CX, Amsterdam
Amsterdam UMC Stichting
Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Medical Oncology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Leids Universitair Medisch Centrum (LUMC)
Medical Oncology, Albinusdreef 2, 2333 ZA, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-04-02 2026-04-14

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-11-10 Netherlands Acceptable
2026-01-27
2026-01-29
2 SUBSTANTIAL MODIFICATION SM-1 2026-03-23 Netherlands Acceptable
2026-04-14
2026-04-14